Regulatory UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy BioPharma DiveNews of the submission, which would be the first for UniQure s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: May 1, 2026) BioPharma Dive News of the submission, which would be the first for UniQure s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launchNext: Parexel buys Vitrana to boost patient safety toolkit Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
